Maina Bhaman is Director of Healthcare Investments at Imperial Innovations and to date has led all of the investment rounds into Myotec Therapeutics. She has over ten years’ start-up experience gained through working at biotechnology ventures in both the US and UK. Previously Maina was a Senior Scientist on the Oncology R&D team at Celltech (previously Oxford Glyco Sciences) where she was responsible for the successful management of several drug discovery projects. Maina’s experience includes Chimeric Therapies, a cell therapy start-up based in Philadelphia and GeneMedicine, a gene therapy company based in Houston. Maina has a BSc from the University of Texas at Austin and an MBA from the Imperial Business School. Maina has led a number of investments in Imperial Innovations’ healthcare portfolio. She was previously was on the board of The Acrobot Co Ltd and is currently also a director of Cell Medica Ltd, Molecular Vision Ltd and IXICO Ltd.